Endovia Health Sciences (EDVA) Net Income towards Common Stockholders Growth (1y) (2013 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Net Income towards Common Stockholders Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.06 Bn | 133.21 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 86.96 Bn | 78.97 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 64.93 Bn | 59.74 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 57.22 Bn | 52.08 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.59 Bn | 44.59 Bn | - | - |
| 6 | BeOne Medicines | 40.43 Bn | 35.33 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.17 Bn | 27.34 Bn | - | -12.04% |
| 9 | Insmed | 27.60 Bn | 26.43 Bn | 358.27 Mn | 95.87% |
| 10 | Endovia Health Sciences | 821,701.01 | 578,999.01 | - | 75.98% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 75.98% |
| Mar 31, 2026 | 34.79% |
| Dec 31, 2025 | 19.79% |
| Sep 30, 2025 | -109.47% |
| Jun 30, 2025 | -56.99% |
| Mar 31, 2025 | 29.86% |
| Dec 31, 2024 | 51.75% |
| Sep 30, 2024 | 16.76% |
| Jun 30, 2024 | 5.05% |
| Mar 31, 2024 | -25.25% |
| Dec 31, 2023 | -25.05% |
| Sep 30, 2023 | -10.23% |
| Jun 30, 2023 | 2.58% |
| Mar 31, 2023 | 37.79% |
| Dec 31, 2022 | 21.37% |
| Sep 30, 2022 | 57.81% |
| Jun 30, 2022 | 12.22% |
| Mar 31, 2022 | -34.94% |
| Dec 31, 2021 | 72.99% |
| Sep 30, 2021 | -433.87% |